Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
about
Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenzaA single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine developmentAssaying the Potency of Influenza VaccinesH5N1 vaccines in humansPreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineH5 influenza, a global update.The avian influenza vaccine Emerflu. Why did it fail?Clinical vaccine development for H5N1 influenza.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetEvaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunizationA live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.Current status and progress of prepandemic and pandemic influenza vaccine development.Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.Influenza A (H5N1) pandemic prototype vaccine Fluval.Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.Role of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development.Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in micePandemic influenza vaccines - the challenges.Aflunov(®): a prepandemic influenza vaccine.Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in miceEvidence of infection with H4 and H11 avian influenza viruses among Lebanese chicken growers.A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthSafety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.Avian influenza A(H5N1) and A(H9N2) seroprevalence and risk factors for infection among Egyptians: a prospective, controlled seroepidemiological studyAvian Influenza A(H5N1) Virus in EgyptVaccine strategies to enhance immune responses in the aged.Baculovirus vector as a delivery vehicle for influenza vaccines.Animal models in virus research: their utility and limitations.Influenza vaccination in the elderly.An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis
P2860
Q21091074-554F3D73-7FD9-4B24-AB48-0A0C9622D2BCQ24656615-02CD98F2-C75E-4E64-8CCB-FCA5ECAB534CQ26783499-AD0984DF-55C1-4639-9CE9-D3FDD023A4B6Q27000896-83EFAE09-D7F9-40EC-A442-4F35849E4416Q27347652-257C883A-714A-4048-92DE-1DFA78FAEA0DQ30151309-050EB93A-7E92-451F-A824-BB5540C1A4FBQ30203302-A6DE130C-0F3A-43FD-92F4-B46891E5F6AAQ30222083-BBEC94A3-E733-4C54-BF2B-337CE0D1E6DEQ30227194-302C1F3A-687C-4DC7-9832-237DCBBCBCF2Q30227975-8DD9A61F-CBDF-4115-861B-C130C74ED0FAQ30359896-185E9EFD-9D1C-4DCC-8BCA-4794E03EA4C8Q30362332-48505619-4699-48C0-AA64-77116C4517ABQ30375784-1B4A708E-B154-4C28-9D8F-31523D31656EQ30375975-11E468C9-846E-4DE3-8D47-B583E77F9D7BQ30376350-713E238C-63E6-4ED5-9FC6-FA05145BB648Q30376553-A01ADACB-6AD9-4779-BB1F-52F88BAC00F1Q30378263-219DB320-9C73-4E4D-AB2D-9D78F633A700Q30389274-96193D39-00E0-4C33-AE76-E2265FCBD751Q30391974-42D82CED-0C98-4852-AD2D-E1EE422ADA2EQ30408091-0709D4BE-59CE-4439-894A-11EA63F2DFB9Q30412628-EEC82B44-8634-4493-AEE2-E494660E198EQ30424758-BEB0CCCF-DE17-4BDC-AF4C-49C0B9A0D2D3Q30429455-985F89B6-68F7-41E9-B445-99F913FFD960Q33409110-A68FD74F-8247-4D78-A9A1-A55081AE9430Q34064724-DC480789-2249-421D-9765-BB3EB751A816Q34289880-256BF142-3AA7-430C-BB79-59680C3479DEQ34497705-B4CFC6DA-174C-4896-883B-601DA83B9FC7Q34498228-5D692930-43EE-41A8-ACBA-A68D91946C23Q34699088-94102BDD-AA12-4C2F-BDCD-DE4ABE66A0B5Q35715601-F806858C-0382-4DB0-A15D-7EB828BBB7B0Q36617093-4692162A-A0F3-4A09-8B95-D14BC130529AQ37179398-45CEF0E4-EFF9-4A46-AB87-84BBF57D6566Q37434539-AE9FB972-4F43-4865-9EEB-D603F8783B40Q38043556-963B5F29-979C-45F6-A364-A5C47B75BA18Q40134515-F6DB487B-A928-432A-9D73-876762A79CD0Q40782869-A0387948-2930-48FB-9F01-8190F0017F0FQ41932790-8097EA71-010B-463F-AAB5-130D064AF1EEQ57094173-99A0A822-EC4A-48FA-B4EB-41D9CE34CFC5
P2860
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Phase I and II randomised tria ...... N1) vaccine in healthy adults.
@en
type
label
Phase I and II randomised tria ...... N1) vaccine in healthy adults.
@en
prefLabel
Phase I and II randomised tria ...... N1) vaccine in healthy adults.
@en
P2093
P1433
P1476
Phase I and II randomised tria ...... 5N1) vaccine in healthy adults
@en
P2093
David Ryan
Georgina Pearce
Jillian Bennet
Katja Höschler
Kelly Papanaoum
Maria C Zambon
Maryanne V Skeljo
Neil T Formica
Russell L Basser
Terry M Nolan
P304
P356
10.1016/J.VACCINE.2008.05.077
P407
P577
2008-06-13T00:00:00Z